基质金属蛋白酶家族在骨关节炎软骨组织中表达的研究

[目的]观察骨关节炎关节软骨中MMP-7、MMP-9、MMP-13和TIMP-1的表达,探讨其与软骨退变的关系及可能的作用机制。[方法]选取20例因骨关节炎行关节置换的软骨组织,常规HE染色观察其组织学形态,ABC免疫组化法观察关节软骨MMP-7、MMP-9、MMP-13和TIMP-1的表达,2例因意外受伤截肢患者的正常膝关节软骨标本作为对照。统计采用Mann-Whitney U非参数检验及相关分析。[结果]骨关节炎关节软骨出现裂隙、纤维化,软骨细胞增多、排列紊乱,并出现大量簇聚软骨细胞和肥大软骨细胞。MMP-7和MMP-13在正常软骨全层均呈低表达,但在退变软骨中的表达则明显增多,光密度值行U检验,两组差异有显著性(P<0.01)。在正常与OA软骨的浅层,MMP-9和TIMP-1的表达无显著性差异(P>0.05);但在深层软骨中,OA软骨MMP-9和TIMP-1的表达较正常软骨明显增多,两组差异有显著性(P<0.01)。[结论]MMP-7,13在OA软骨全层表达均多于正常软骨;MMP-9,13仅在OA软骨深层出现过多表达。MMPs与TIMPs的失衡是导致关节软骨发生组织学退变的原因之一。     

人类恶性胶质瘤细胞中变异型IκBα对基质金属蛋白酶-2、-9表达的调节作用

目的 探讨变异型IκBα（IκBαM）基因对人类多形性胶质母细胞瘤（GBM）细胞中基质金属蛋白酶（MMP）-2、-9表达的调控作用。方法 通过构建质粒、基因转染以及IκBαM蛋白表达的筛选，建立稳定表达IκBαM的人类GBM细胞株，运用逆转录．聚合酶链反应（RT-PCR）技术检测细胞及肿瘤组织内MMP-2、MMP-9在RNA水平的表达；并将肿瘤细胞植入裸鼠皮下制作异位移植瘤生长动物模型，进一步通过免疫组织化学染色方法分析MMP-2、MMP-9的蛋白表达。结果RT-PCR结果显示，体外试验中，MMP-2与对应GAPDH平均吸光度值的比值分别为1．450±0．180（G36Δ-W）、0．292±0．040（G36Δ-M）、1．187±0．140（G36Δ-P）和1．463±0．160（G36Δ）；MMP-9与对应GAPDH平均吸光度值的比值分别为1．424±0．130（G36Δ-W）、0．275±0．020（G36Δ-M）、1．357±0．180（G36Δ-P）和1．608±0．240（G36Δ）。在体内试验中，MMP-2与对应GAPDH平均吸光度值的比值分别为0．870±0．060（G36Δ-W）、0．024±0．010（G36Δ-M）、0．785±0．070（G36Δ-P）和0．686±0．070（G36Δ）；MMP-9与对应GAPDH平均吸光度值的比值分别为0．768±0．010（G36Δ-W）、0．054±0．010（G36Δ-M）、0．802±0．020（G36Δ-P）和0．746±0．020（G36Δ）。在体外和体内试验中，G36Δ-M组与其余各组之间的差异均有统计学意义（P〈0．05），而其他3组间差异无统计学意义。体内试验肿瘤组织中，MMP-2及MMP-9的在G36Δ-M组中的染色显著低于G36Δ、G36Δ-W和G36Δ-P组；而在G36Δ、G36Δ-W和G36Δ-P三组间的表达差异无统计学意义。结论 IκBαM基因可以在分子及蛋白水平显著抑制人类恶性胶质瘤中MMP-2、MMP-9的表达，减弱肿瘤细胞的侵袭和浸润能力。     

不同大小机械牵张力对MC3T3-E1成骨样细胞MMP-13/TIMP-1 mRNA表达的影响

目的:研究不同大小的机械牵张力对成骨细胞MMP-13/TIMP-1mRNA表达的影响。方法:通过自制的多通道细胞牵张应力加载系统对小鼠成骨样细胞MC3T3-E1同时施加6%、12%和18%的机械牵张力,作用24h后,用RT-PCR方法检测细胞受力后MMP-13/TIMP-1mRNA表达的变化。结果:细胞受力后,其MMP-13/TIMP-1mRNA表达随牵张力值的增大明显增加。结论:不同大小的机械牵张力可以影响成骨细胞的MMP-13/TIMP-1mRNA表达,进而影响骨改建。     

Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer

BACKGROUND: Cellular events mediated by the Tie2 receptor are important to tumor neovascularization. Despite the complex interplay of the best-characterized Tie2 ligands, angiopoietins 1 and 2, Ang2 is purportedly "proangiogenic" in the presence of vascular endothelial growth factor. We examined whether in vivo administration of an RNA aptamer that specifically blocks Ang 2 would inhibit tumor angiogenesis and growth. METHODS: Ang2-mediated Tie2 receptor phosphorylation was assessed in vitro in the absence and presence of aptamer coupled to polyethylene glycol. IN VIVO ANGIOGENESIS ASSAY: CT26 murine colon carcinoma cells expressing green fluorescent protein were delivered into mouse dorsal skinfold window chambers. Animals received daily intraperitoneal injections of phosphate-buffered saline, low-dose (Ang2 aptamer-LD; 1 mg/kg/d), or high-dose aptamer (Ang2 aptamer-HD; 10 mg/kg/d). Vascular length density was measured under fluorescence microscopy. PRIMARY TUMOR GROWTH: CT26 cells expressing luciferase were injected into flanks of BALB/c mice to allow tumor growth monitoring by bioluminescence imaging. Animals received continuous phosphate-buffered saline or aptamer (1 mg/kg/d) via ALZET pumps. Tumors were assessed for CD31/PECAM-1 immunostaining and Hoechst dye uptake. RESULTS: Pegylated aptamer inhibited Tie2 phosphorylation. Systemic aptamer administration reduced vascular length density (P < or = 0.03) and decreased bioluminescence emission (P < 0.04), corresponding to 50% decrease in tumor volume (P = 0.04). Control tumors displayed abundant vascular marker staining, in contrast to tumors from aptamer-treated animals. CONCLUSIONS: in vivo administration of a clinically relevant, pegylated RNA aptamer specifically designed against Ang2 inhibited tumor angiogenesis and growth. These findings support targeted Ang2 inhibition as a relevant anti-angiogenic, anti-neoplastic strategy.     

放射后肝癌细胞MMP-2表达、活性的变化及其对侵袭性的影响

目的 探讨放射后肝癌细胞侵袭潜能的变化及其机制.方法 以不同剂量(0、4、8Gy)高能X线照射人肝癌低转移潜能细胞株MHCC97L.明胶酶谱法检测放射后24、48、72、96 h细胞培养上清液金属蛋白酶(MMP)-2活性,细胞免疫荧光法检测放射后24、48和72 h细胞内MMP-2蛋白表达,Transwell法测定放射后48和96 h细胞的侵袭能力.结果 放射后细胞MMP-2蛋白分泌及活性增强并与放射剂量及时间相关,8 Gy放射后48 h MMP-2蛋白活性最高,达到对照组的2倍.0、4、8 Gy放射后48 h穿过transwell小室的细胞数分别为7.2±1.9、13.2±2.7和31.2±7.2(P＜0.05),放射后96 h组间差异无统计学意义.结论 放射后肝癌细胞侵袭潜能短暂增强,放射诱导细胞MMP-2分泌及活性增强是侵袭性增强的原因之一.     

mitofusin-2对乳腺癌细胞RECK基因表达及MMPs活性的影响

目的 探讨线粒体融合素基因-2(mitofusin-2)对乳腺癌MCF-7细胞株中RECK表达及MMP-9,MMP-2活性的影响.方法 利用脂质体lipofectamine2000将构建的重组真核表达质粒pEGFPmfn2转染MCF-7细胞.RT-PCR检测细胞mfn2和RECK基因mRNA的转录水平;Weastem Blot法检测mfn2及RECK蛋白的表达;明胶酶谱试验检测转染前后MMP-9及MMP-2的活性.结果 转染pEGFP-mfn2质粒的MCF-7细胞可以稳定高表达Mfn2;RECK基因在转染空质粒组和未转染组细胞中无表达;转染mfn2基因后RECK基因mRNA转录及蛋白的表达显著升高,且MMP-9及MMP-2的活性显著降-低(P＜0.05).结论 mfn2基因可激活MCF-7细胞中RECK基因的表达,并显著抑制其MMP-9及MMP2的活性.该途径可能是mfn2基因抗肿瘤作用的新机制.     

原发性肝癌患者肝切除术后血浆MMP-2和TIMP-2浓度变化及生长抑素干预

目的 观察肝癌患者肝切除后血浆MMP-2和TIMP-2浓度变化及生长抑素干预。方法 20例肝癌切除患者随机分成2组,常规治疗组和生长抑素治疗组,每组各10例,生长抑素治疗组给于生长抑素治疗。结果 肝切除后,血浆MMP-2浓度明显上升,血浆TIMP-2浓度明显下降,应用SST能降低MMP-2浓底,升高TIMP-2浓度。结论 肝切除后应用SST可能对抑制肿瘤复发有益     

2型糖尿病血清Apelin-13的变化水平与骨质疏松症的关系

目的探讨血清Apelin-13的水平与骨密度(bone mineral density,BMD)等指标的关系,确定Apelin-13对2型糖尿病患者骨质疏松症的影响。方法纳入2015年1月至2017年9月在我院就诊的152例2型糖尿病患者,将患者分为3组,其中骨质疏松组38例,骨量减少组50例,正常组64例。记录所有患者的临床资料,包括年龄、性别、身高、体重、体质量指数和疾病持续时间。收集血液样品用于测量Apelin-13、I型前胶原氨基端前肽(procollagen type-I N propeptide,PINP)、I型胶原羧基端肽(pyridinoline cross-linked carboxyterminal telopeptide of typeⅠcollagen,ICTP),并用双能X线吸收扫描仪测量患者的BMD。结果 Apelin-13水平在骨质疏松组明显低于骨量减少组和正常组(P0.05),骨量减少组明显低于正常组(P0.05)。相关分析显示,Apelin-13水平与BMD和PINP呈正相关(P0.05),与年龄、ICTP呈负相关(P0.05)。结论本研究表明Apelin-13和BMD、ICTP与PINP之间存在密切关系。     

Prognostic significance of tumor angiogenesis,Ki 67, p53 oncoprotein,epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study

BACKGROUND: This study prospectively examines the prognostic role of p53 oncoprotein (p53), Ki67-antigen (Ki67), tumor angiogenesis (MVD), epidermal growth factor receptor (EGFR), and HER2 receptor protein (HER2) expression in Chinese with undifferentiated nasopharyngeal carcinoma (NPC). METHODS: Seventy-eight Chinese were recruited from October 1995 to July 1997 at the Prince of Wales Hospital, Hong Kong. Pretreatment immunohistochemical preparations of the primary tumor were made, and clinical data were collected prospectively until October 30, 2000. The markers were correlated with overall survival (OS), disease-free survival (DFS), time to progression (TTP), and UICC stage. RESULTS: On univariate analysis, EGFR expression correlated with poorer OS (p =.0001), DFS (p =.01), shorter TTP (p =.0001), and advanced T stage (p =.036). Strong EGFR expression, when compared with weak or moderate, was associated with poorer OS (p =.04) and shorter TTP in a subgroup of patients with UICC stage III-IV disease. HER2 expression was associated with advanced UICC stage (p =.006). The presence of p53 expression correlated with poorer DFS (p =.01) and a trend toward shorter TTP (p =.06). No correlation was found with Ki67-antigen or MVD. On multivariate analysis, only EGFR expression was significantly linked to shorter OS and TTP. CONCLUSIONS: EGFR expression in undifferentiated NPC is associated with a poor clinical outcome. A prognostic role of p53 and HER2 expression is suggestive but not consistently defined in this study. The relatively high prevalence of positive staining for EGFR supports the use of molecular targeted therapy in this disease.     

Rapid healing of femoral defects in rats with low dose sustained BMP2 expression from PEGDA hydrogel microspheres

Current strategies for bone regeneration after traumatic injury often fail to provide adequate healing and integration. Here, we combined the poly (ethylene glycol) diacrylate (PEGDA) hydrogel with allogeneic “carrier” cells transduced with an adenovirus expressing BMP2. The system is unique in that the biomaterial encapsulates the cells, shielding them and thus suppressing destructive inflammatory processes. Using this system, complete healing of a 5 mm‐long femur defect in a rat model occurs in under 3 weeks, through secretion of 100‐fold lower levels of protein as compared to doses of recombinant BMP2 protein used in studies which lead to healing in 2–3 months. New bone formation was evaluated radiographically, histologically, and biomechanically at 2, 3, 6, 9, and 12 weeks after surgery. Rapid bone formation bridged the defect area and reliably integrated into the adjacent skeletal bone as early as 2 weeks. At 3 weeks, biomechanical analysis showed the new bone to possess 79% of torsional strength of the intact contralateral femur. Histological evaluation showed normal bone healing, with no infiltration of inflammatory cells with the bone being stable approximately 1 year later. We propose that these osteoinductive microspheres offer a more efficacious and safer clinical option over the use of rhBMP2. © 2013 Orthopaedic Research Society Published by Wiley Periodicals, Inc. J Orthop Res 31:1597–1604, 2013     

Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer

BACKGROUND: Transforming growth factor beta (TGFbeta) over-expression in prostate cancer has been shown to promote tumor progression and neo-vascularization. In this study, we have investigated the efficacy and the potential mechanism of a TGFbeta antagonist, a recombinant soluble betaglycan (sBG), as a prostate cancer therapeutic agent after systemic administration in a xenograft model. METHODS: Recombinant sBG was delivered continuously via ALZET osmotic pumps or by daily bolus i.p. injection at 4.2 mg/kg/day for 14 days in human prostate cancer DU145 xenograft bearing nude mice. Tumors were analyzed for their size, blood volume by hemoglobin assay, microvessel density (MVD) by CD-31 immunostaining, and apoptosis by TUNEL assay. Matrix metalloproteinase-9 (MMP-9) activity and expression in the DU145 conditioned media were determined by gelatin zymography and Western blotting, respectively. Tissue sections were stained with a polyclonal antibody to MMP-9 using an immuno-fluorescence method. RESULTS: Continuous or bolus administration of sBG showed a similar significant inhibition of DU145 xenograft growth associated with a reduced tumor blood volume and MVD, and an enhanced intra-tumoral apoptosis. Treatment with sBG inhibited both endogenous and TGFbeta-induced MMP-9 activity and expression in a dose-dependent manner in vitro and reduced in vivo MMP-9 expression in DU145 xenografts. CONCLUSIONS: Our results for the first time indicate that TGFbeta blockade by systemic sBG administration can inhibit DU145 prostate xenograft growth and angiogenesis. The inhibition is likely in part mediated by the attenuation of TGFbeta-induced MMP-9 expression.     

Effects of vitamin K2, vitamin D, and calcium on the bone metabolism of rats in the growth phase

 Using 168 female Sprague-Dawley rats, we determined whether the peak bone mass could be increased, and which drugs would be effective in suppressing the rate of decrease in bone mass by continuous administration from childhood. At the age of 3 months, these 168 rats were divided into five groups depending on the type of diet that they were fed (control, regular; group A, vitamin K₂; group B, vitamin D; group C, high calcium; group D, vitamins D and K₂ and high calcium) and kept to the age of 16 months. Dual-energy X-ray absorptiometry (DXA) was used to measure the bone mineral density of the femoral epiphysis and microcomputed tomography (CT) to analyze its fine structure. The average bone mass increased rapidly with age and reached a peak at the age of 8 months. Peak bone mass for the four drug administration groups was higher than that for the control group. Among these four groups, the peak bone mass was the highest in group C and the rate of decrease the smallest in group D. The results of the present animal study suggest that the peak bone mass of humans can be raised by consuming sufficient amounts of vitamins K₂ and D and calcium continuously from childhood, and that this diet will suppress the rate of decrease in bone mass, thus ultimately preventing bone fractures caused by osteoporosis. Received: June 12, 2001 / Accepted: January 22, 2002     

人脑胶质瘤血管生成素-2表达及其与管生成和脑水肿的关系

目的 研究血管生成素.2(Ang-2)基因在人脑胶质瘤表达及其与胶质瘤血管生成及瘤周水肿的关系。方法 用半定量逆转录-聚合酶链反应(RT-PCR)、免疫组织化学方法测定42例人脑胶质瘤和8例正常脑组织中Ang-2 mRNA及其蛋白表达情况。用免疫组织化学方法检测肿瘤微血管密度(MVD)。结果 正常脑组织中无或弱表达Ang-2。42例胶质瘤组织中均有Ang-2 mRNA表达,不同级别间Ang-2 mRNA的表达差异有显著性(P<0.05)。随着脑胶质瘤恶性程度的增加,Ang-2 mRNA的表达增高(r=0.894,P<0.01)。免疫组织化学结果显示,胶质瘤细胞及肿瘤血管内皮细胞中均有Ang-2蛋白表达。Ang-2 mRNA表达与MVD、脑水肿指数(EI)显著相关(分别为r=0.853,P<0.01;r=0.784,P<0.01)。结论 Ang-2可能参与胶质瘤血管生成,对胶质瘤瘤周脑水肿及恶性进展有促进作用。     

Augmentation of surgical angiogenesis in vascularized bone allotransplants with host‐derived a/v bundle implantation,fibroblast growth factor‐2, and vascular endothelial growth factor administration

We have previously shown experimental transplantation of living allogeneic bone to be feasible without long‐term immunosuppression by development of a recipient‐derived neoangiogenic circulation within bone. In this study, we examine the role of angiogenic cytokine delivery with biodegradable microspheres to enhance this process. Microsurgical femoral allotransplantation was performed from Dark Agouti to Piebald Virol Glaxo rats. Poly(D,L‐lactide‐co‐glycolide) microspheres loaded with buffer, basic fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), or both, were inserted intramedullarly along with a recipient‐derived arteriovenous (a/v) bundle. FK‐506 was administered daily for 14 days, then discontinued. At 28 days, bone blood flow was measured using hydrogen washout. Microangiography, histologic, and histomorphometric analyses were performed. Capillary density was greater in the FGF+VEGF group (35.1%) than control (13.9%) (p < 0.05), and a linear trend was found from control, FGF, VEGF, to FGF+VEGF (p < 0.005). Bone formation rates were greater with VEGF (p < 0.01) and FGF+VEGF (p < 0.05). VEGF or FGF alone increased blood flow more than when combined. Histology rejection grading was low in all grafts. Local administration of vascular and fibroblast growth factors augments angiogenesis, bone formation, and bone blood flow from implanted blood vessels of donor origin in vascularized bone allografts after removal of immunosuppression. © 2010 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 28:1015–1021, 2010     

邻苯二甲酸二乙基己酯及代谢产物MEHP对幼鼠睾丸组织TGF-β1表达和端粒酶活性的影响

目的:观察邻苯二甲酸二乙基己酯(DEHP)及代谢产物邻苯二酸-单-2-乙基己酯(MEHP)对幼鼠睾丸组织转化生长因子-β1(TGF-β1)表达和端粒酶活性的影响,探讨DEHP和MEHP损害生精功能可能的机制。方法:生后2周龄的Wistar雄性幼鼠96只,随机分8组,每组12只。随机选择1组行生理盐水[0.9%NS0.2 ml/(kg.d),喂养3周]灌胃,作为正常对照组(NC组);再选1组行环磷酰胺[CTX 100 mg/(kg.d),喂养1周]灌胃,作为阳性对照组(PC组);余各组分别用DEHP、MEHP按低剂量[100 mg/(kg.d),喂养3周]、中剂量[200 mg/(kg.d),喂养2周]、高剂量[300 mg/(kg.d),喂养1周]灌胃制作动物模型。观察不同时期、不同剂量下睾丸组织精子形态变化,光镜下计数精子头部及畸形率;应用免疫组化SABC法及RT-PCR法检查睾丸组织TGF-β1的表达,并测定面密度;ELISA法检查睾丸组织中端粒酶活性。结果:①睾丸组织内精子形态变化:用药组精子数量减少,出现精子断头、无钩、双尾等畸形精子;在光镜下精子计数,与NC组比较,用药各组精子头部显著减少(P<0.05),畸形率增加(P<0.05),但高剂量短时间用药组与低剂量长时间用药组比较,差异无统计学意义(P>0.05)。②睾丸组织TGF-β1的表达变化:NC组低表达,DEHP及代谢产物MEHP染毒各组生精细胞内表达增多,PC组大量表达,阳性细胞呈黄褐色,主要分布于胞膜及胞质。NC组面密度为0.156 0±0.003 5、TGF-β1mRNA为1.51±0.20,PC组面密度为0.534 0±0.003 1、TGF-β1 mRNA为8.43±1.75;用药的DEHP组面密度均值为0.289 0±0.003 6、TGF-β1 mRNA为3.83±1.57,MEHP组面密度均值为0.284 0±0.003 1、TGF-β1 mRNA为3.51±1.41,用药各组与NC组、PC组比较差异有统计学意义(P<0.01),但高剂量短时间用药组与低剂量长时间用药组比较,差异无统计学意义(P>0.05);③睾丸组织中端粒酶活性:与NC组比较,用药各组睾丸组织中端粒酶活性下降(P<0.05),高剂量短时间用药组与低剂量长时间用药组比较,差异无统计学意义(P>0.05)。结论:DEHP及代谢产物MEHP对幼鼠生精功能有明显损害,其损害机制可能与DEHP及代谢产物MEHP诱导睾丸组织TGF-β1的表达水平升高、端粒酶活性降低有关。     

仙灵骨葆胶囊对骨质疏松性骨折大鼠骨生长因子及骨折愈合的影响

目的 探讨仙灵骨葆胶囊对骨质疏松性骨折大鼠骨生长因子BMP-2、IGF-1表达及骨折愈合的影响。方法 48只雌性SD大鼠随机分为：假手术组、模型组、雌二醇组、仙灵骨葆组，12只/组，采用“双侧卵巢切除术+右侧股骨干骨折髓内固定术”构建骨质疏松性骨折大鼠模型，评估骨折愈合情况，检测股骨骨痂BMD、股骨骨生物力学指标和血清骨代谢相关指标，检测骨痂BMP-2、IGF-1蛋白表达。结果 模型组较假手术组骨折愈合评分、股骨痂BMD、股骨骨生物力学指标（最大载荷、最大应力、最大位移）、骨痂BMP-2和IGF-I阳性表达均显著降低（P<0.05），雌二醇组、仙灵骨葆组较模型组骨折愈合评分、股骨痂BMD、股骨骨生物力学指标、骨痂BMP-2和IGF-I阳性表达均显著升高（P<0.05），均以仙灵骨葆组最高。模型组较假手术组血清骨代谢指标（BGP、PICP、TRACP-5b）均显著升高（P<0.05），雌二醇组、仙灵骨葆组较模型组血清骨代谢指标均显著降低（P<0.05），以仙灵骨葆组最低。结论 仙灵骨葆胶囊可能通过介导提高骨质疏松性骨折大鼠骨生长因子BMP-2和IGF-1表达，改善骨代谢，加速骨痂形成，增加骨密度，提高骨生物力学，促进骨折愈合。     

HHcy ED大鼠血浆内Hcy的含量对阴茎海绵体CO/HO-2影响的研究

目的:研究高同型半胱氨酸血症(HHcy)勃起功能障碍大鼠体内一氧化碳/血红素加氧酶2(CO/HO-2)体系的变化。方法:雄性4周龄Wistar大鼠40只,体重280～310 g,正常喂养1周后,随机分为正常对照组(A组,10只),余30只给予3%蛋氨酸饲料4周后,测定尾静脉血Hcy,将Hcy>16.0μmol/L的大鼠确定为HHcy,由此确定造模成功。将模型组随机均分为B组(HHcy大鼠模型组,继续给予3%蛋氨酸饲料喂养),C组(HHcy盐酸甜菜碱治疗组,每天继续给予3%蛋氨酸饲料喂养,下午定时给予60 mg/kg甜菜碱,0.3 ml生理盐水溶液灌胃)和D组[每日给与锌卟啉IX腹腔内注射45μmol/(kg.d)],4周后处死大鼠提取标本血检测Hcy含量、阴茎海绵体中Hcy的含量及阴茎组织CO测定。分别于4周和8周2个时间点进行阿朴吗啡实验。结果:比较4组大鼠血浆Hcy浓度、阴茎勃起次数、阴茎海绵体组织CO浓度及阴茎组织血管中HO-2阳性细胞数量的检测结果,与A组[(12.55±0.82)μmol/L、(1.88±0.05)次、(10.55±1.73)μmol/L、6 059±1 257]比较,B组[(25.01±0.94)μmol/L、(0.70±0.05)次、(9.51±1.52)μmol/L、2 595±514]血浆中Hcy水平显著上升(P<0.05),阴茎勃起次数、CO的含量与HO-2阳性细胞均下降(P<0.05或P<0.01),并且Hcy与阴茎勃起次数呈负相关性(P<0.01);C组[(14.37±0.47)μmol/L、(1.18±0.08)次、(10.36±1.56)μmol/L、6 295±1 156]与B组比较,阴茎海绵体内Hcy含量下降,而CO与HO-2含量明显升高,阴茎勃起次数明显升高,有统计学意义(P<0.05或P<0.01)。结论:阴茎海绵体中的CO含量及阴茎海绵体HO-2表达减低可能是导致HHcy大鼠勃起功能障碍的原因之一。甜菜碱降低血浆Hcy浓度,增加阴茎海绵体中CO含量,是治疗HHcy勃起功能障碍的机制之一。